Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

$ 18.73 0.28 (1.52%) Market Cap: 21.08 Bil Enterprise Value: 37.43 Bil PE Ratio: 0 PB Ratio: 3.31 GF Score: 59/100

Q2 2024 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Jul 31, 2024

$17.43 (+6.22%)

Earnings
Q1 2024 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
May 08, 2024

$15.74 (+12.83%)

Earnings
Q4 2023 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Jan 31, 2024

$12.1 (+3.15%)

Earnings
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Q3 2023 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Nov 08, 2023

$9.15 (+1.22%)

Earnings
Teva Pharmaceutical Industries Ltd to Discuss the Collaboration with Sanofi to Deliver Inflammatory Bowel Disease Treatment Call Transcript
Oct 04, 2023
Teva Pharmaceutical Industries Ltd at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023
Q2 2023 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Aug 02, 2023

$9.25 (+11.58%)

Earnings
Teva Pharmaceutical Industries Ltd Investor Day Transcript
May 18, 2023
Q1 2023 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
May 10, 2023

$8.35 (-8.24%)

Earnings
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript
Mar 14, 2023
Q4 2022 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Feb 08, 2023

$9.92 (-8.91%)

Earnings
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Nov 03, 2022

$8.61 (-1.71%)

Earnings
Q2 2022 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Jul 27, 2022

$9.14 (+28.37%)

Earnings
Q1 2022 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
May 03, 2022

$8.6 (+0.82%)

Earnings
Q4 2021 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Feb 09, 2022

$8.99 (+8.44%)

Earnings
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Q3 2021 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Oct 27, 2021

$8.93 (-4.90%)

Earnings
Q2 2021 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Jul 28, 2021

$9.99 (+12.00%)

Earnings
Q1 2021 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Apr 28, 2021

$10.12 (-2.41%)

Earnings
Teva Pharmaceutical Industries Ltd at JPMorgan Global High Yield & Leveraged Finance Conference (Virtual) Transcript
Mar 02, 2021
Q4 2020 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Feb 10, 2021

$11.92 (-6.95%)

Earnings
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Nov 05, 2020

$8.61 (-6.51%)

Earnings
Q2 2020 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Aug 05, 2020

$12.66 (+7.29%)

Earnings
Q1 2020 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
May 07, 2020

$11.55 (+10.21%)

Earnings
Q4 2019 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Feb 12, 2020

$13.45 (+9.08%)

Earnings
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Jan 13, 2020
Q3 2019 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Nov 07, 2019

$8.47 (+4.57%)

Earnings
Q2 2019 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Aug 07, 2019

$7.29 (+3.26%)

Earnings
Q1 2019 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
May 02, 2019

$14.9 (-2.17%)

Earnings
Q4 2018 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Feb 13, 2019

$17.63 (-7.79%)

Earnings

Q2 2021 Teva Pharmaceutical Industries Ltd Earnings Call Transcript

Jul 28, 2021 / 12:00PM GMT

Release Date Price: $9.99 (+12.00%)

Transcript 10-Q8-K

Operator

Good day, and thank you for standing by. Welcome to the Teva Second Quarter 2021 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

And I would now like to hand the conference over to your speakers today, and Mr. Kevin Mannix, Senior Vice President, Head of Investor Relations. Please go ahead, sir.

Kevin C. Mannix

Teva Pharmaceutical Industries Limited - SVP of IR

Thank you, Ella, and thank you, everyone, for joining us today to discuss Teva's Second Quarter 2021 Financial Results. Joining me on today's call is Kare Schultz, Teva's Chief Executive Officer; Eli Kalif, Teva's Chief Financial Officer; and Brendan O'Grady, Teva's Head of North America Commercial.

We hope you've had an opportunity to review our press release, which was issued about an hour ago. A copy of the release as well as a copy of the slides being presented on this call can be found on our website at www.tevapharm.com

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.